薬研第２４号
平成８年６月２５日

各都道府県衛生主管部（局）長　殿






厚生省薬務局研究開発振興課長

医薬品の一般的名称について（通知）

今般、医薬品一般的名称命名申請のあった物質につき、新たに一般的名称を別表１、別表２及び別表３のとおり定めたので、御了知の上、別表４の「既に通知された一般的名称等の変更」とも併せ、関係方面に周知方御配慮願いたい。

別表１は、医薬品名称調査会においてＪＡＮが決定されたが、まだＩＮＮとの整合が図られる可能性のある物質について、別表２は、医薬品名称調査会においてＪＡＮが決定され、かつＩＮＮとの整合も図られたことが確認された物質について、別表３は、ＩＮＮを定めないとされているものについてまとめたものである。なお、別表２中、＊を付した品目は、その遊離体又は無水物についてＩＮＮが定められているものである。

別表２

登録番号 ＪＡＮ（日本名） ＪＡＮ（英　名）	構造式
7-8-1＊ 塩酸デュロキセチン duloxetine hydrochloride	
7-8-2＊ 塩酸ピオグリタゾン pioglitazone hydrochloride	
7-8-4 ロルノキシカム lornoxicam	
7-8-5＊ セフチオフルナトリウム ceftiofur sodium	
7-9-2＊ 塩酸バラシクロビル valaciclovir hydrochloride	

International Nonproprietary Names for Pharmaceutical Substances

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances*, the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Recommended International Nonproprietary Names (Rec. INN): List 33

Lists of proposed (1–65) and recommended (1–31) international nonproprietary names can be found in Cumulative List No. 8, 1992.

Recommended International Nonproprietary Name (Latin, English)	*Chemical Name or Description and Molecular Formula*
alestramustinum alestramustine	estradiol 3-[bis(2-chloroethyl)carbamate], 17-ester with L-alanine $C_{26}H_{36}Cl_2N_2O_4$
alglucerasum alglucerase	glucosylceramidase (human placenta isoenzyme protein moiety reduced) $C_{2532}H_{3854}N_{672}O_{711}S_{16}$ (*for non-glycosylated protein*)
alovudinum alovudine	3'-deoxy-3'-fluorothymidine $C_{10}H_{13}FN_2O_4$
altumomabum altumomab	immunoglobulin G 1 (mouse monoclonal ZCE025 anti-human antigen CEA), disulfide with mouse monoclonal ZCE025 light chain, dimer
amesergidum amesergide	*N*-cyclohexyl-1-isopropyl-6-methylergoline-8β-carboxamide $C_{25}H_{35}N_3O$
amitivirum amitivir	1,3,4-thiadiazole-2-carbamonitrile $C_3H_2N_4S$
andolastum andolast	4,4'-di-1*H*-tetrazol-5-ylbenzanilide $C_{15}H_{11}N_9O$
ardeparinum natricum ardeparin sodium	Sodium salt of depolymerized heparin obtained by peroxide degradation (at elevated temperature) of heparin from pork intestinal mucosa; the end chain structure appears to be the same as the starting material with no unusual sugar residues present; the low molecular weight heparin produced differs from the starting material in molecular weight only; the average relative molecular mass range is 5,500 to 6,500 daltons, 98 per cent of which ranging between 2,000 and 15,000; the degree of sulfation is approximately 2,7 per disaccharidic unit.

* *Official Records of the World Health Organization*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9).

Recommended International Nonproprietary Name (Latin, English)	*Chemical Name or Description and Molecular Formula*
clinprostum clinprost	(+)-methyl (3a*S*,5*R*,6*R*,6a*S*)-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-[(*E*)-(3*S*)-3-hydroxy-1-octenyl]-2-pentalenevalerate $C_{22}H_{36}O_4$
deferipronum deferiprone	3-hydroxy-1,2-dimethyl-4(1*H*)-pyridone $C_7H_9NO_2$
dexniguldipinum dexniguldipine	(+)-(*R*)-3-(4,4-diphenylpiperidino)propyl methyl 1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-3,5-pyridinedicarboxylate $C_{36}H_{39}N_3O_6$
dezinamidum dezinamide	3-[(α,α,α-trifluoro-*m*-tolyl)oxy]-1-azetidinecarboxamide $C_{11}H_{11}F_3N_2O_2$
dimiracetamum dimiracetam	(±)-dihydro-1*H*-pyrrolo[1,2-*a*]imidazole-2,5(3*H*,6*H*)-dione $C_6H_8N_2O_2$
dorzolamidum dorzolamide	(4*S*,6*S*)-4-(ethylamino)-5,6-dihydro-6-methyl-4*H*-thieno[2,3-*b*]thiopyran-2-sulfonamide 7,7-dioxide $C_{10}H_{16}N_2O_4S_3$
drospirenonum drospirenone	(6*R*,7*R*,8*R*,9*S*,10*R*,13*S*,14*S*,15*S*,16*S*,17*S*)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-hexadecahydro-10,13-dimethylspiro-[17*H*-dicyclopropa[6,7:15,16]cyclopenta[*a*]phenanthrene-17,2'(5'*H*)-furan]-3,5'(2*H*)-dione $C_{24}H_{30}O_3$
duloxetinum duloxetine	(+)-(*S*)-*N*-methyl-γ-(1-naphthyloxy)-2-thiophenepropylamine $C_{18}H_{19}NOS$
ecabapidum ecabapide	*m*-[[[(3,4-dimethoxyphenethyl)carbamoyl]methyl]amino]-*N*-methylbenzamide $C_{20}H_{25}N_3O_4$
ecadotrilum ecadotril	*N*-[(*S*)-α-(mercaptomethyl)hydrocinnamoyl]glycine, benzyl ester, acetate (ester) $C_{21}H_{23}NO_4S$
enadolinum enadoline	*N*-methyl-*N*-[(5*R*,7*S*,8*S*)-7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-4-benzofuranacetamide $C_{24}H_{32}N_2O_3$
enazadremum enazadrem	4,6-dimethyl-2-[(6-phenylhexyl)amino]-5-pyrimidinol $C_{18}H_{25}N_3O$
enofelastum enofelast	(*E*)-4'-fluoro-3,5-dimethyl-4-stilbenol $C_{16}H_{15}FO$
epoetinum alfa epoetin alfa	1-165-erythropoietin (human clone λHEPOFL 13 protein moiety), glycoform α $C_{809}H_{1301}N_{229}O_{240}S_5$ (*for non-glycosylated protein*)
epoetinum beta epoetin beta	1-165-erythropoietin (human clone λHEPOFL 13 protein moiety), glycoform β $C_{809}H_{1301}N_{229}O_{240}S_5$ (*for non-glycosylated protein*)